Cancer Institute A national cancer institute
designated cancer center

Susan Knox

Publication Details

  • Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier PHARMACEUTICAL RESEARCH Wartchow, C. A., Alters, S. E., Garzone, P. D., Li, L. Y., Choi, S., DeChene, N. E., Doede, T., Huang, L., Pease, J. S., Shen, Z. M., Knox, S. J., Cleland, J. L. 2004; 21 (10): 1880-1885

    Abstract:

    In order to improve the in vitro and in vivo efficacy of an integrin antagonist (IA) of the extracellular domain of the alphavbeta3 integrin, a receptor upregulated on tumor neovasculature, the IA was attached to the surface of a dextran-coated liposome (DCL). IA-DCLs were characterized in vitro, and the pharmacokinetic and antitumor properties were assessed in vivo.The in vitro binding properties were measured with purified integrin, endothelial cells, and melanoma cells. The pharmacokinetic parameters were measured in healthy mice with 14C-labeled IA-DCLs and anti-tumor efficacy was assessed with the M21 human melanoma xenograft mouse model.In vitro, IC50 values for IA-DCLs and IA are similar, and IA-DCLs inhibit cell proliferation relative to controls. IA-DCLs are stable in serum, and the pharmacokinetic half-life in mice is 23 h. In the M21/mouse model, statistically significant inhibition of tumor growth was observed for mice treated with IA-DCLs, whereas controls including saline, DCLs lacking IA, and cyclo(RGDfV) were ineffective. Increased apoptosis and a reduction in vessel counts relative to controls were present in tumors from animals treated with IA-DCLs.These results demonstrate that IA-DCLs are potent anti-angiogenic therapeutic agents with superior in vivo activity and pharmacology compared to unmodified IA.

    View details for Web of Science ID 000224532900022

    View details for PubMedID 15553236

Stanford Medicine Resources:

Footer Links: